Bio-Techne Corp (TECH) Valuation

The valuation assessment reveals a stark disconnect between Bio-Techne's current price and its fundamental performance. The GoodMoat Target of $24.66 suggests an intrinsic value less than half the current price of $52.37, resulting in a negative margin of safety of approximately -112%. According to the GoodMoat framework, a margin of safety below 10% is considered 'Unfavourable,' and a negative figure indicates severe overvaluation. The P/E multiple of 101x is exceptionally high, especially when contrasted with the company's negative YoY revenue growth of -0.4% and a profit margin of only 6.7%. This P/E is far above what would be reasonable even for a high-growth company, let alone one experiencing a revenue contraction. The low Free Cash Flow Yield of 3.1% further indicates that the price is not supported by strong cash generation. While the debt level is moderate, the combination of extreme valuation multiples, declining growth, and low returns on equity (4.2%) suggests the stock is expensive relative to its current quality and growth profile. A value investor would find the risk/reward profile unfavourable, as the price demands near-perfect future execution with no room for error. Analysis based on data as of 2024-05-15.